We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Enovis Boosts Surgical Robotics Portfolio With eCential Acquisition
Read MoreHide Full Article
Key Takeaways
Enovis agreed to acquire eCential Robotics for 155M upfront, plus up to 35M euros in milestone payments.
ENOV shares fell more than 16% after the deal, which is expected to create a 2027 EBITDA margin headwind.
Enovis expects margins to expand again in 2028, with free cash flow conversion improving from 2027.
Enovis Corporation (ENOV - Free Report) recently entered into a binding agreement to acquire France-based eCential Robotics for an upfront enterprise value of 155 million euros, with up to 35 million euros in milestone-based payments. The deal, expected to close by the end of 2026, will add robotic automation capabilities to Enovis' ASTRA enabling technology platform and expand its surgical technology portfolio.
From an investor perspective, the acquisition strengthens Enovis' long-term position in the fast-growing orthopedic robotics market by combining eCential's modular robotic platform with its ARVIS augmented reality system. While the transaction is expected to create a 100-basis-point adjusted EBITDA margin headwind in 2027, management expects margin expansion to resume in 2028 alongside improving free cash flow conversion, making the deal a strategic investment in future growth.
Likely Trend of ENOV Stock Following the News
However, following the announcement, shares of ENOV dipped more than 16% on Monday. Year to date, shares of the company have lost 22.9% against the industry’s 13.4% growth. However, the S&P 500 has risen 11.8% in the same timeframe.
The acquisition is expected to strengthen Enovis' long-term competitive position by expanding its enabling technology ecosystem into surgical robotics, a fast-growing segment of orthopedic procedures. Integrating eCential Robotics' modular robotic platform with ASTRA and the ARVIS augmented reality system should create a more comprehensive suite of precision tools, helping Enovis deepen surgeon adoption, accelerate product innovation and capture greater share in robotic-assisted surgery. The planned robotics center of excellence in Grenoble also adds engineering talent and intellectual property that could support sustained innovation and future growth beyond 2027.
ENOV currently has a market capitalization of $1.42 billion.
Image Source: Zacks Investment Research
Details of the News
The acquisition gives Enovis a stronger technological foundation by adding eCential Robotics' more than 15 years of expertise in computer-assisted surgery, robotics engineering and surgical automation to its existing enabling technology portfolio. The French company's modular robotic platform is expected to integrate with Enovis' ASTRA platform and ARVIS augmented reality system, creating a broader suite of precision tools for orthopedic procedures that can improve surgical accuracy, operating room efficiency and patient outcomes. Enovis also plans to establish a robotics center of excellence in Grenoble, France, preserving eCential's engineering talent, intellectual property and innovation capabilities while continuing to support the company's existing commercial partnerships.
From a financial standpoint, Enovis intends to fund the transaction through cash on hand and its existing revolving credit facility, balancing near-term investment with long-term growth ambitions. Management expects the acquisition to create a 150-basis-point deal-related dilution to adjusted EBITDA margin in 2027, partially offset by 50 basis points of underlying improvement, resulting in a net 100-basis-point headwind before margins resume year-over-year expansion in 2028. The company also projects free cash flow conversion to improve to 50% in 2027, exceeding $100 million, with further gains in 2028 and 2029.
The deal remains subject to French works council consultation, a definitive acquisition agreement and regulatory approvals before its anticipated year-end 2026 closing.
Industry Prospects Favoring the Market
Going by the data provided by Grand View Research, the global surgical robots market size is projected to increase from $17.2 billion in 2026 to $45.6 billion by 2033, at a CAGR of 14.9% from 2026 to 2033.
The industry is benefiting from the growing adoption of robotic-assisted minimally invasive procedures, rising demand for greater surgical precision and increased use of advanced robotic instruments and accessories across hospitals and surgical centers.
Other News
Recently, Enovis launched CT-RevitL, the next-generation veterinary photobiomodulation (PBM) laser therapy system under its Companion Animal Health business in the United States. The system features enhanced mobility, improved clinical performance and COMPASS intelligent treatment guidance technology to deliver more precise and consistent therapy while simplifying veterinary workflows. Built on more than 150 published PBM studies, CT-RevitL targets the growing demand for non-drug pain management and tissue healing solutions in veterinary care, with international expansion planned in later phases.
ENOV’s Zacks Rank & Key Picks
Currently, ENOV has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and The Cooper Companies (COO - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.
COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.
View the Zacks #1 Rank List
Image: Bigstock
Enovis Boosts Surgical Robotics Portfolio With eCential Acquisition
Key Takeaways
Enovis Corporation (ENOV - Free Report) recently entered into a binding agreement to acquire France-based eCential Robotics for an upfront enterprise value of 155 million euros, with up to 35 million euros in milestone-based payments. The deal, expected to close by the end of 2026, will add robotic automation capabilities to Enovis' ASTRA enabling technology platform and expand its surgical technology portfolio.
From an investor perspective, the acquisition strengthens Enovis' long-term position in the fast-growing orthopedic robotics market by combining eCential's modular robotic platform with its ARVIS augmented reality system. While the transaction is expected to create a 100-basis-point adjusted EBITDA margin headwind in 2027, management expects margin expansion to resume in 2028 alongside improving free cash flow conversion, making the deal a strategic investment in future growth.
Likely Trend of ENOV Stock Following the News
However, following the announcement, shares of ENOV dipped more than 16% on Monday. Year to date, shares of the company have lost 22.9% against the industry’s 13.4% growth. However, the S&P 500 has risen 11.8% in the same timeframe.
The acquisition is expected to strengthen Enovis' long-term competitive position by expanding its enabling technology ecosystem into surgical robotics, a fast-growing segment of orthopedic procedures. Integrating eCential Robotics' modular robotic platform with ASTRA and the ARVIS augmented reality system should create a more comprehensive suite of precision tools, helping Enovis deepen surgeon adoption, accelerate product innovation and capture greater share in robotic-assisted surgery. The planned robotics center of excellence in Grenoble also adds engineering talent and intellectual property that could support sustained innovation and future growth beyond 2027.
ENOV currently has a market capitalization of $1.42 billion.
Image Source: Zacks Investment Research
Details of the News
The acquisition gives Enovis a stronger technological foundation by adding eCential Robotics' more than 15 years of expertise in computer-assisted surgery, robotics engineering and surgical automation to its existing enabling technology portfolio. The French company's modular robotic platform is expected to integrate with Enovis' ASTRA platform and ARVIS augmented reality system, creating a broader suite of precision tools for orthopedic procedures that can improve surgical accuracy, operating room efficiency and patient outcomes. Enovis also plans to establish a robotics center of excellence in Grenoble, France, preserving eCential's engineering talent, intellectual property and innovation capabilities while continuing to support the company's existing commercial partnerships.
From a financial standpoint, Enovis intends to fund the transaction through cash on hand and its existing revolving credit facility, balancing near-term investment with long-term growth ambitions. Management expects the acquisition to create a 150-basis-point deal-related dilution to adjusted EBITDA margin in 2027, partially offset by 50 basis points of underlying improvement, resulting in a net 100-basis-point headwind before margins resume year-over-year expansion in 2028. The company also projects free cash flow conversion to improve to 50% in 2027, exceeding $100 million, with further gains in 2028 and 2029.
The deal remains subject to French works council consultation, a definitive acquisition agreement and regulatory approvals before its anticipated year-end 2026 closing.
Industry Prospects Favoring the Market
Going by the data provided by Grand View Research, the global surgical robots market size is projected to increase from $17.2 billion in 2026 to $45.6 billion by 2033, at a CAGR of 14.9% from 2026 to 2033.
The industry is benefiting from the growing adoption of robotic-assisted minimally invasive procedures, rising demand for greater surgical precision and increased use of advanced robotic instruments and accessories across hospitals and surgical centers.
Other News
Recently, Enovis launched CT-RevitL, the next-generation veterinary photobiomodulation (PBM) laser therapy system under its Companion Animal Health business in the United States. The system features enhanced mobility, improved clinical performance and COMPASS intelligent treatment guidance technology to deliver more precise and consistent therapy while simplifying veterinary workflows. Built on more than 150 published PBM studies, CT-RevitL targets the growing demand for non-drug pain management and tissue healing solutions in veterinary care, with international expansion planned in later phases.
ENOV’s Zacks Rank & Key Picks
Currently, ENOV has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and The Cooper Companies (COO - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.
COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.